Cancer Stem Cell News Volume 12.17 | May 03 2023

    0
    144








    2023-05-03 | CSCN 12.17


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 12.17 – 3 May, 2023
    TOP STORY

    Inhibition of VEGF Binding to Neuropilin-2 Enhances Chemosensitivity and Inhibits Metastasis in Triple-Negative Breast Cancer

    Using triple negative breast cancer as a model, researchers demonstrated that aNRP2-10 could be used to isolate CSCs from heterogeneous tumor populations and inhibit CSC function and epithelial-to-mesenchymal transition.
    [Science Translational Medicine]

    Abstract
    Explore neural organoid technologies with this free wallchart from STEMCELL and Nature Neuroscience
    PUBLICATIONSRanked by the impact factor of the journal

    Hyperbaric Oxygen Activates Enzyme-Driven Cascade Reactions for Cooperative Cancer Therapy and Cancer Stem Cells Elimination

    A multifunctional cascade bioreactor, based on the self-assembly of pH-responsive hydroxyethyl starch prodrugs, copper ions, and glucose oxidase, was engineered, empowered by hyperbaric oxygen for efficient cooperative therapy against aggressive breast cancers.
    [Advanced Science]

    Full Article

    Cancer Stem Cell Assay-Guided Chemotherapy Improves Survival of Patients with Recurrent Glioblastoma in a Randomized Trial

    In a randomized clinical trial, the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improved the survival of patients with recurrent glioblastoma over physician-chosen chemotherapy.
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract

    YAP/BRD4-Controlled ROR1 Promotes Tumor-Initiating Cells and Hyperproliferation in Pancreatic Cancer

    Researchers
    showed that a cellular subpopulation with partial epithelial-mesenchymal transition-like signature marked by high expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) was the origin of heterogeneous tumor cells in pancreatic ductal adenocarcinoma.

    [Embo Journal]

    Full ArticleGraphical Abstract

    Chi3l1 Is a Modulator of Glioma Stem Cell States and a Therapeutic Target in Glioblastoma

    Investigators showed that chitinase 3-like 1 (Chi3l1) altered the state of glioma stem cells (GSCs) to support tumor growth. Exposure of patient-derived GSCs to Chi3l1 reduced the frequency of CD133+SOX2+ cells and increased the CD44+Chi3l1+ cells.
    [Cancer Research]

    Abstract

    Collagen I-DDR1 Signaling Promotes Hepatocellular Carcinoma Cell Stemness via Hippo Signaling Repression

    The authors found that in advanced hepatocellular carcinoma tissues, collagen I was upregulated, which was consistent with the expression of its receptor DDR1. Collagen I-induced DDR1 activation enhanced HCC cell stemness in vitro and in vivo.
    [Cell Death & Differentiation]

    Abstract

    MSI2 Promotes Translation of Multiple IRES-Containing Oncogenes and Virus to Induce Self-Renewal of Tumor Initiating Stem-Like Cells

    Scientists tested if Musashi 2 (MSI2) promoted MYC and viral mRNA translation to induce self-renewal via an internal ribosome entry sequence.
    [Cell Death Discovery]

    Full ArticleGraphical Abstract

    Thioredoxin Facilitates Hepatocellular Carcinoma Stemness and Metastasis by Increasing BACH1 Stability to Activate the AKT/mTOR Pathway

    Functional studies showed that thioredoxin promoted hepatocellular carcinoma (HCC) stemness properties and facilitated HCC metastasis both in vitro and in vivo.
    [FASEB Journal]

    Abstract

    Dihydroartemisinin Inhibited Stem Cell-Like Properties and Enhanced Oxaliplatin Sensitivity of Colorectal Cancer via AKT/mTOR Signaling

    Researchers found that dihydroartemisinin (DHA) inhibited cell viability in HCT116 and SW620 cells. Moreover, DHA decreased cell clonogenicity, and improved oxaliplatin sensitivity.
    [Drug Development Research]

    Abstract

    MMP9 and TYROBP Affect the Survival of Circulating Tumor Cells in Clear Cell Renal Cell Carcinoma by Adapting to Tumor Immune Microenvironment

    Scientists searched for genes differentially expressed in circulating tumor cells (CTCs) by analyzing four CTCs and primary tumor gene expression datasets in the GEO database.
    [Scientific Reports]

    Full Article

    KIF15 Knockdown Inhibits the Development of Endometrial Cancer by Suppressing Epithelial-Mesenchymal Transition and Stemness through Wnt/β-Catenin Signaling

    Investigators detected the expression level of kinesin family member 15 (KIF15) in a microarray of endometrial cancer tissues by immunohistochemical staining and analyzed the correlation between the expression level of KIF15 and the pathological characteristics of patients.
    [Environmental Toxicology]

    Full Article
    Enjoy your weekend. Your cells will too. Reduce medium acidosis with mTeSR™ Plus.
    REVIEWS

    Mitochondria in Cancer Stem Cells: Achilles Heel or Hard Armor

    The authors introduce the roles played by mitochondria and related mechanisms in CSC stemness maintenance, metabolic transformation, and chemoresistance.
    [Trends in Cell Biology]

    Abstract

    Long Non-Coding RNAs: Fundamental Regulators and Emerging Targets of Cancer Stem Cells

    Scientists examine and highlight the long non-coding RNAs (lncRNAs) with their regulatory functions specific to CSCs. They discuss the difficulties and various methods involved in identifying lncRNAs that can play a particular role in regulating and maintaining CSCs.
    [Biochimica Et Biophysica Acta-Reviews On Cancer]

    Abstract

    Extirpating the Cancer Stem Cell Hydra: Differentiation Therapy and Hyperthermia Therapy for Targeting the Cancer Stem Cell Hierarchy

    Investigators summarize the progress made so far in integrating hyperthermia therapy with existing modules of differentiation therapy.
    [Clinical And Experimental Medicine]

    Abstract
    INDUSTRY AND POLICY NEWS

    PharmaEssentia Initiates Phase IIIb Trial of Ropeginterferon Alfa-2b-Njft Investigatng New Dosing Regimen for Patients with Polycythemia Vera (PV)

    PharmaEssentia USA Corporation announced that the first patients are now being dosed in ECLIPSE PV, a Phase IIIb clinical study evaluating an accelerated dosing schedule for ropeginterferon alfa-2b-njft using a prefilled syringe for the treatment of adults with PV.
    [PharmaEssentia (Business Wire)]

    Press Release
    FEATURED EVENT

    Balancing Genome Fidelity and Plasticity

    May 4 – 7, 2023
    Riviera Maya, Mexico

    > See All Events

    JOB OPPORTUNITIES

    Research Fellow – Aging and Cancer Stem Cell

    The National University of Singapore – Singapore, Singapore

    Research/Senior Scientist – Oncology Drug Discovery Biotherapeutics

    Novartis – Cambridge, Massachusetts, United States

    Postdoctoral Research Associate – Oncology

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Postdoctoral Fellow – Cancer Biology

    Wake Forest University – Winston Salem, North Carolina, United States

    Postdoctoral Position – Cancer Metabolism, Epigenetics, and Hematopoiesis Research

    University of Texas Health Science Center – San Antonio, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter